5 Health Services Stocks Pushing Industry Growth

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 11 points (0.1%) at 15,533 as of Tuesday, July 30, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,505 issues advancing vs. 1,392 declining with 116 unchanged.

The Health Services industry currently sits up 1.0% versus the S&P 500, which is up 0.2%. A company within the industry that increased today was CareFusion ( CFN), up 1.3%. On the negative front, top decliners within the industry include Express Scripts ( ESRX), down 2.3%, UnitedHealth Group ( UNH), down 0.8% and Cigna ( CI), down 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Grifols ( GRFS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Grifols is up $0.25 (0.8%) to $31.55 on light volume. Thus far, 58,836 shares of Grifols exchanged hands as compared to its average daily volume of 623,600 shares. The stock has ranged in price between $31.31-$31.73 after having opened the day at $31.31 as compared to the previous trading day's close of $31.30.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $17.4 billion and is part of the health care sector. Shares are up 20.9% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Waters Corporation ( WAT) is up $1.16 (1.2%) to $100.79 on average volume. Thus far, 211,689 shares of Waters Corporation exchanged hands as compared to its average daily volume of 516,700 shares. The stock has ranged in price between $100.24-$101.09 after having opened the day at $100.38 as compared to the previous trading day's close of $99.63.

Waters Corporation operates as an analytical instrument manufacturer in the United States and internationally. Waters Corporation has a market cap of $8.6 billion and is part of the health care sector. Shares are up 14.4% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Waters Corporation a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Waters Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Waters Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Catamaran ( CTRX) is up $0.69 (1.4%) to $51.93 on light volume. Thus far, 634,095 shares of Catamaran exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $51.60-$52.36 after having opened the day at $51.66 as compared to the previous trading day's close of $51.24.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $10.7 billion and is part of the health care sector. Shares are up 9.9% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Catamaran a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, compelling growth in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Catamaran Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Covidien ( COV) is up $0.53 (0.9%) to $61.29 on light volume. Thus far, 661,916 shares of Covidien exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $60.89-$61.44 after having opened the day at $61.02 as compared to the previous trading day's close of $60.76.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $28.7 billion and is part of the health care sector. Shares are up 5.2% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Covidien Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Baxter International ( BAX) is up $0.83 (1.1%) to $73.66 on light volume. Thus far, 1.2 million shares of Baxter International exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $72.92-$73.77 after having opened the day at $72.96 as compared to the previous trading day's close of $72.83.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $39.6 billion and is part of the health care sector. Shares are up 9.5% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Baxter International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Baxter International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again